Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024.
Orion Research Foundation grants EUR 1,112,000 for research in 2024 Read More »
En el universo primitivo, poco después del Big Bang, solo existían elementos químicos ligeros como el hidrógeno, el helio y el litio. Los elementos más pesados que esos, como el oxígeno, se formaron posteriormente mediante reacciones de fusión nuclear …
Los elementos químicos para la vida surgieron en el universo antes de lo creído Read More »
InnoCare Pharma announced that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.
Cybin Reports Second Quarter Financial Results and Recent Business Highlights Read More »
In today’s challenging environment, here are some creative ways biotechs have found to survive and thrive.
Renalytix plc today reported financial results for the fiscal first quarter ended September 30, 2023.
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 Read More »
Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.
Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets Read More »
Crucial Data Solutions (CDS), the only SaaS platform to empower customer-driven global clinical trials for web and mobile environments, and nmible, a provider of cost effective clinical trial payment solutions, announced today they have formed a strategic
Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023 Read More »
Xsphera Biosciences, a leading biotechnology company specializing in ex vivo testing of oncology therapeutics on patient-excised tumor tissue, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I
Xsphera Biosciences and NEX-I Collaborate to Advance Oncology Drug Research Read More »
